Current Issue : October - December Volume : 2018 Issue Number : 4 Articles : 6 Articles
Carbamazepine is known to produce the side effect of euphoria. As such, it lends itself to being a drug of abuse, particularly in\nthe adolescent population. This retrospective study evaluated carbamazepine abuse, treatment course, and associated morbidity\nin Chinese adolescents. The median dose of carbamazepine resulting in overdose was 2,000mg (800ââ?¬â??5,000). Patients were largely\nfrom urban-rural fringe areas (76.47%, 52.94%) with school performance within the last 1/3 range and (52.94%) unsupervised by\nparents. 35.29% experienced an obvious sense of euphoria. All patients had nervous system symptoms, 6 (35.29%) cases developed\ncoma (GCS < 8), and 5 (29.41%) cases experienced convulsion. Four cases were treated with hemodialysis. The incidence rate in\nyoung patients with repeat carbamazepine use and without the supervision of parents was higher than that in first-time users (5/7\nversus 4/10), but the difference was not significant.The toxic dose of repeat users was 3428 Ã?± 1035mg, significantly higher than that\nof 1470 Ã?± 646mg in first-time users (...
Objective. Chromium-containing traditional Chinese medicine Tianmai Xiaoke tablet (TMXKT) is approved for treating newly\ndiagnosed type 2 diabetes mellitus (T2DM) in China.This review aimed to compile the evidence from randomized clinical trials\n(RCTs) and quantify the effects of TMXKT on newly diagnosed T2DM. Methods. Seven online databases were investigated up\nto March 20, 2017. The meta-analysis included RCTs investigating the treatment of newly diagnosed T2DM, in which TMXKT\ncombined with conventional therapy was compared with placebo or conventional therapy. The risk of bias was evaluated using\nthe Cochrane Collaboration tool. The estimated mean difference (MD) and the standardized mean difference were within 95%\nconfidence intervals (CI) with respect to the interstudy heterogeneity. The outcomes were measured using fasting blood glucose\n(FBG), 2-h postprandial blood glucose (2hPG), glycosylated hemoglobin A1c (HbA1c), and body mass index (BMI) levels. Results.\nTMXKT combined with conventional therapy lowered FBG level (MD = âË?â??0.68, 95% CI âË?â??0.90 to âË?â??0.45, ...
Diabetic patients have an increased risk of osteoporosis-associated fractures. However, the results of most studies of the effects of\ndiabetes on bone mass in patients with type 2 diabetes (T2DM) have been contradictory. To clarify these conflicting findings, we\ninvestigated the effects of diabetic serum on the proliferation and osteogenic differentiation of mesenchymal stem cells (MSCs).\nWe used human sera from subjects with different levels of glycemic control to culture the MSCs and induce osteogenic\ndifferentiation. The rate of MSC proliferation differed when MSCs were cultured with sera from diabetic subjects with different\nlevels of hyperglycemia. Hyperglycemic sera promoted MSC proliferation to some extent, but all the diabetic sera inhibited the\ndifferentiation of MSCs to osteoblasts. The effects of type 2 diabetic sera on the proliferation and osteogenic differentiation of\nMSCs are closely related to glycemic control. Our data demonstrate the importance of stratifying the study population\naccording to glycemic control in clinical research into diabetic osteoporosis....
Postoperative ileus is one of the most important and common complications after abdominal\nsurgery. This single-blind randomized clinical trial study was conducted with the aim of evaluating\nthe effect of oral pyridostigmine (60 mg) on the duration and frequency of response to the treatment\nof ileus after abdominal surgery on 40 patients in two 20-subject groups of oral pyridostigmine\n(interventional) and starch (control) in 2015. All 40 people completed the study process and entered\nthe final analysis. In the oral Pyridostigmin group (60 mg) the mean response time for the disposal of\ngas and stool were 5.4 �± 4.7 h and 4.9 �± 3.4 h, respectively. Most of the participants 10 (50%) (Disposal\nof stool) responded to treatment 4 h after the administration of oral pyridostigmine. In the starch\ngroup, the mean response time for the disposal of gas and stool were 32.4 �± 9.9 h and 36.2 �± 10.3 h,\nrespectively. The mean treatment response time in two groups showed a significant difference\nbetween both groups (p = 0.001). Regarding the frequency of response to treatment (disposal of gas\nor stool) in the 24-h period after the initiation of treatment in the oral pyridostigmine group, 95%\n(n = 19) of the subjects responded to the treatment in the first 24 h. However, in the starch group,\nonly 50% (n = 10) responded to treatment in the first 24 h, the results showed a significant difference\nbetween the two groups (p = 0.001). The results indicate that oral pyridostigmine can be used as a\nsimple and effective treatment for gastrointestinal ileus....
Medium chain triglycerides (MCTs) are ketogenic and might reduce adverse effects of keto-induction and improve time to ketosis\nand the tolerability of very low carbohydrate diets. This study investigates whether MCT supplementation improves time to\nnutritional ketosis (NK), mood, and symptoms of keto-induction. We compared changes in beta-hydroxybutyrate (BOHB), blood\nglucose, symptoms of keto-induction, and mood disturbance, in 28 healthy adults prescribed a ketogenic diet, randomised to\nreceive either 30 ml of MCT, or sunflower oil as a control, three times per day, for 20 days. The primary outcome measured was the\nachievement of NK (ââ?°Â¥0.5 mmolÃ?·LâË?â??1 BOHB). Participants also completed a daily Profile of Mood States and keto-induction\nsymptom questionnaire. MCT resulted in higher BOHB at all time points and faster time to NK, a result that failed to reach\nsignificance. Symptoms of keto-induction resulted from both diets, with a greater magnitude in the control group, except for\nabdominal pain, which occurred with greater frequency and severity in the MCT-supplemented diet. There was a possibly\nbeneficial effect on symptoms by MCT, but the effect on mood was unclear. Based on these results, MCTs increase BOHB\ncompared with LCT and reduce symptoms of keto-induction. It is unclear whether MCTs significantly improve mood or time to\nNK. The trial was registered by the Australia New Zealand Clinical Trial Registry ACTRN12616001099415....
Periodontal disease consists of chronic gingival inflammation characterized by both degradation of the periodontal connective\ntissue and alveolar bone loss. Drug therapy is used as an auxiliary treatment method in severe chronic periodontitis, aggressive\nperiodontitis, and periodontitis-associated systemic disease. Nal-P-113, a modified antimicrobial peptide, specifically replaces the\nhistidine residues of P-113 with the bulky amino acid ...
Loading....